Redcare Pharmacy: Growth Accelerating, But The Margin And Losses Tell A Harder Story

Redcare Pharmacy's H1 2026 numbers are better than most people expect from a company still reporting GAAP net losses. Revenue grew 19% to €1.7 billion. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization - a rough proxy for operating cash generation) jumped 62% to €44 million, pushing the margin to 2.6% for the half-year. Q2 alone delivered a 3.5% adjusted EBITDA margin, the highest in a decade. International, long a drag, turned positive.

Management raised full-year revenue guidance from 13-15% to 15-17%. The stock sits around €63-64, implying an enterprise value-to-sales multiple of roughly 0.5x. At that level, the market is essentially betting that the growth is temporary, the margins won't hold, or the losses are more structural than the adjusted numbers suggest.

That is the practical question: has the market priced the right story, or is the discount wider than the business case deserves?

What accelerated in H1 2026

The topline acceleration is broad, not concentrated in one segment. Non-Rx revenue grew 13% in Q2; Rx revenue grew 34%. DACH revenue (Germany, Austria, Switzerland) rose 21% to €696 million. International grew 17% to €158 million.

The standout is Rx in Germany. Prescription revenue there surged 58% in Q2 and 57% for the first half, reaching €180 million in the quarter and €348 million for H1. Management flagged that the underlying Rx growth rate in Germany has been running in the high-50% range, sustained over multiple quarters. That is not a one-off surge - it is the structural driver.

Customer growth is keeping pace. The active customer base reached 14.7 million at the end of Q2, up 1.2 million from a year ago and up half a million in the quarter alone. The average shopping basket value rose 4% to €68, and the Rx basket value grew 14%. Customer satisfaction metrics stayed high, with a Net Promoter Score of 74 overall and 77 for e-Rx.

Profitability improved on the adjusted basis. Selling and distribution costs fell from 18.4% of revenue to 16.0%, driven by more efficient marketing spending and operating leverage. Adjusted admin expenses were 2.7% versus 2.9% last year. DACH adjusted EBITDA grew to €28 million (4.0% margin), and International flipped to €1.4 million of positive adjusted EBITDA from a €2 million loss a year ago.

The harder story: margins, losses, and debt

Adjusted EBITDA is not GAAP earnings, and that distinction matters. Gross profit margin compressed to 22.1% in Q2 from 23.8% a year earlier. The year-over-year decline is a direct function of the growing share of Rx revenue, which carries lower gross margins than non-Rx. As the Rx mix expands - which is exactly the growth driver the company wants - gross margin comes under pressure. That is not a one-quarter blip; it's a structural trade-off of the business model shift.

On the bottom line, GAAP net loss widened to €5.8 million for H1 2026 from €1.5 million a year ago, or €0.29 per share versus €0.07. The widening loss reflects the gross margin compression plus the costs of building the Rx infrastructure and international operations. Management has not yet shown a clear path to GAAP profitability in 2026.

The balance sheet adds another layer. Total debt sits at roughly €355 million against €475 million of shareholder equity, implying a net debt-to-equity ratio near 50%. That is not crisis-level, but it is not trivial either for a company still losing money on a GAAP basis. The debt limits flexibility if growth stalls or margins don't improve as fast as planned.

The July signal

The most important detail from the earnings call is July trading. Management described it as softer than the Q2 pace - group growth came in slightly below 20%, and non-Rx growth in Germany was in single digits. That is not a breakdown, but it is a signal that the high-50% Rx growth and 20% group growth rates from Q2 may not carry forward at the same velocity. The company also flagged that a new signature-on-delivery requirement for prescriptions could cost under €1 million annually - a relatively small operational friction, but another cost to track.

Valuation: cheap or fair?

At €63-64, Redcare Pharmacy trades at roughly 0.5x trailing sales. The market is pricing this like a company struggling to grow while burning cash.

Wall Street consensus sits around €80 per share - roughly 25% above current levels. That target assumes the growth and margin trajectory holds, not that it reaccelerates dramatically. The gap between the current price and the consensus target is the market's discount for execution risk, margin compression, and debt.

The rating call

Here is the risk/reward setup. The operating engine - Rx growth in Germany, customer acquisition, international profitability, margin efficiency in selling and marketing - is accelerating. The company raised guidance with the Q2 print rather than letting it slide. The valuation at 0.5x sales is the kind of multiple that only makes sense if you believe the growth is unsustainable or the losses will deepen materially.

The counter-evidence is real but narrower. Gross margin will compress as Rx grows - that's baked in. GAAP losses will persist in 2026. July was softer. Debt is meaningful. But none of these factors destroys the thesis. They temper it.

The valuation has not moved with the operating improvement. That is the disconnect. The stock is cheap enough to absorb the margin pressure and the GAAP losses while still offering upside if the 15-17% growth and 2.5-3.0% EBITDA margin guidance materializes.

Hold, with a clear bias toward buying on weakness. The case is not for aggressive position-building at current levels because the margin compression, GAAP losses, and July softness warrant caution. But the valuation offers enough margin of safety that a dip below €55-60 - the area where the market would be pricing in a genuine growth failure - creates an asymmetric risk/reward. If Q3 results confirm that the adjusted EBITDA margin stays at or above 3% and Rx Germany growth remains above 40%, the rating upgrades to a full Buy.

Conversely, if Q3 shows Rx growth decelerating below 30%, gross margin collapsing below 20%, or the company cutting guidance, the thesis breaks. Watch Q3 closely.